|
1
|
Lee WR: The role of androgen deprivation
therapy combined with prostate brachytherapy. Urology. 60(3 Suppl
1): S39–S44. 2002. View Article : Google Scholar
|
|
2
|
Merrick GS, Butler WM, Wallner KE,
Galbreath RW, Allen ZA and Kurko B: Efficacy of neoadjuvant
bicalutamide and dutasteride as a cytoreductive regimen before
prostate brachytherapy. Urology. 68:116–120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nishiyama T, Tomita Y and Takahashi K:
Influence of androgen deprivation therapy on volume of anatomic
zones of prostate in patients with prostate cancer using magnetic
resonance imaging. Urology. 63:917–921. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zelefsky MJ, Leibel SA, Burman CM, Kutcher
GJ, Harrison A, Happersett L and Fuks Z: Neoadjuvant hormonal
therapy improves the therapeutic ratio in patients with bulky
prostate cancer treated with three-dimensional conformal radiation
therapy. Int J Radiat Oncol Biol Phys. 29:755–761. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Henderson A, Langley SM and Laing RW: Is
bicalutamide equivalent to goserelin for prostate volume reduction
before radiation therapy? A prospective, observational study. Clin
Oncol (R Coll Radiol). 15:318–321. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shearer RJ, Davies JH, Gelister JS and
Dearnaley DP: Hormonal cytoreduction and radiotherapy for carcinoma
of the prostate. Br J Urol. 69:521–524. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whittington R, Broderick GA, Arger P,
Malkowicz SB, Epperson RD, Arjomandy B and Kassaee A: The effect of
androgen deprivation on the early changes in prostate volume
following transperineal ultrasound guided interstitial therapy for
localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys.
44:1107–1110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carter SS, Torp-Pedersen ST and Holm HH:
Ultrasound-guided implantation techniques in treatment of prostate
cancer. Urol Clin North Am. 16:751–762. 1989.PubMed/NCBI
|
|
9
|
Rasch C, Barillot I, Remeijer P, Touw A,
van Herk M and Lebesque JV: Definition of the prostate in CT and
MRI: A multi-observer study. Int J Radiat Oncol Biol Phys.
43:57–66. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Badiozamani KR, Wallner K, Cavanagh W and
Blasko J: Camparability of CT-based and TRUS-based prostate
volumes. Int J Radiat Oncol Biol Phys. 43:375–378. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furuya R, Hisasue S, Furuya S, Saitoh N,
Ogura H, Takahashi S and Tsukamoto T: Fate of seminal vesicles and
prostate after medical castration: How long is the optimal duration
of neoadjuvant treatment for prostate cancer before radiation?
Urology. 72:417–421. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Majumder K, Nilsson S, Johansson H, Ullén
A, Lennernäs B, Bergenmar M and Brandberg Y: Higher sexual interest
with androgen receptor inhibitor monotherapy than with castration
plus an androgen receptor inhibitor in prostate cancer patients
treated with curative radiotherapy, but otherwise small
health-related quality of life differences: A randomised
prospective 18-month follow-up study. Eur J Cancer. 65:43–51. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aaronson NK, Ahmedzai S, Bergman B,
Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman
SB, de Haes JC, et al: The European organization for research and
treatment of cancer QLQ-C30: A quality-of-life instrument for use
in international clinical trials in oncology. J Natl Cancer Inst.
85:365–376. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Andel G, Bottomley A, Fosså SD,
Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G,
Akdas A, et al: An international field study of the EORTC QLQPR25:
A questionnaire for assessing the health-related quality of life of
patients with prostate cancer. Eur J Cancer. 44:2418–2424. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kucway R, Vicini F, Huang R, Stromberg J,
Gonzalez J and Martinez A: Prostate volume reduction with androgen
deprivation therapy before interstitial brachytherapy. J Urol.
167:2443–2447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alsadius D, Olsson C, Pettersson N, Tucker
SL, Wilderäng U and Steineck G: Patient-reported gastrointestinal
symptoms among long-term survivors after radiation therapy for
prostate cancer. Radiother Oncol. 112:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gillespie C, Goode C, Hackett C and
Andreyev HJ: The clinical needs of patients with chronic
gastrointestinal symptoms after pelvic radiotherapy. Aliment
Pharmacol Ther. 26:555–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hopfgarten T, Adolfsson J, Henningsohn L,
Onelöv E and Steineck G: The choice between a therapy-induced
long-term symptom and shortened survival due to prostate cancer.
Eur Urol. 50:280–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Andreyev HJ, Vlavianos P, Blake P,
Dearnaley D, Norman AR and Tait D: Gastrointestinal symptoms after
pelvic radiotherapy: Role for the gastroenterologist? Int J Radiat
Oncol Biol Phys. 62:1464–1471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lilleby W, Fosså SD, Waehre HR and Olsen
DR: Long-term morbidity and quality of life in patients with
localized prostate cancer undergoing definitive radiotherapy or
radical prostatectomy. Int J Radiat Oncol Biol Phys. 43:735–743.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Abany M, Helgason AR, Cronqvist AK,
Svensson C, Wersäll P and Steineck G: Long-term symptoms after
external beam radiation therapy for prostate cancer with three or
four fields. Acta Oncol. 41:532–542. 2002. View Article : Google Scholar : PubMed/NCBI
|
